On Invalid Date, Barinthus Biotherapeutics (NASDAQ: BRNS) reported Q4 2023 earnings per share (EPS) of -$0.45, up 21.05% year over year. Total Barinthus Biotherapeutics earnings for the quarter were -$17.29 million. In the same quarter last year, Barinthus Biotherapeutics's earnings per share (EPS) was -$0.57.
As of Q1 2024, Barinthus Biotherapeutics's earnings has grown year over year. Barinthus Biotherapeutics's earnings in the past year totalled -$73.35 million.
What is BRNS's earnings date?
Barinthus Biotherapeutics's earnings date is Invalid Date. Add BRNS to your watchlist to be reminded of BRNS's next earnings announcement.
What was BRNS's revenue last quarter?
On Invalid Date, Barinthus Biotherapeutics (NASDAQ: BRNS) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Barinthus Biotherapeutics's revenue was $6.46 million.
What was BRNS's revenue growth in the past year?
As of Q1 2024, Barinthus Biotherapeutics's revenue has grown -98.21% year over year. This is 263.82 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Barinthus Biotherapeutics's revenue in the past year totalled $802.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.